Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + olaparib + paclitaxel
- Development stage
- Phase 3
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of carboplatin (a platinum-based chemotherapy), olaparib (a PARP inhibitor), and paclitaxel (a taxane chemotherapy). This regimen works through multiple mechanisms: carboplatin induces DNA cross-linking, olaparib inhibits DNA repair by blocking PARP1/2, and paclitaxel prevents microtubule formation during cell division. The combination has shown synergistic effects in cancer treatment, particularly for ovarian cancer and other advanced solid tumors.
- Other names
- olaparib plus weekly carboplatin and paclitaxel
02
Targets
DNAPARP1 (Poly (adp-ribose) polymerase 1)PARP2 (Poly (adp-ribose) polymerase 2)TUBB (Tubulin (alpha and beta subunits))Microtubule
Beyond the preview
Go deeper on carboplatin + olaparib + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + olaparib + paclitaxel.